PRL and ovarian cancer: Recombinant human prolactin antagonists are potential drugs that inhibit target prolactin receptors in dopamine-resistant prolactinomas, breast cancer, prostate cancer, and ovary cancer, in all cases where autocrine PRL acts as growth promoting agent, or even for pain release and to avoid hair loss (O'Sullivan and Bates 2016).